ICON ICLR · NASDAQ
$168.14 -1.20% (-$2.04)
Summary
51 / 100 · Bulios Score
What speaks for it
- It bought back its own shares for $750.0M in the last fiscal year, 5.7% of its market value.
- Out of every 100 USD of revenue, 16 USD is left as free cash.
What to watch
- Earnings per share fell by 22% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 4.0 USD is left as net profit.
- It earns only 4.8 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 39.9 USD for 1 USD of yearly profit. Over the last five years it was 58.5 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 24% a year over 5 years. Over the last 3 years it grew by 2.1% a year. For the next fiscal year analysts expect revenue to fall by 1.4%. Earnings per share fell by 22% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 78 USD
- Sales and administration 12 USD
- Taxes and other 6.2 USD
- Net profit 4.0 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 4.0 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 17
- Hold 11
- Sell 2
Today's price within the analysts' price targets
The average target of $173.82 is 3.4% above today's price. 57% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2012By product
- Clinical Research 92%
- Central Laboratory 7.8%
By region
- IRELAND 39%
- UNITED STATES 31%
- Rest Of Europe 19%
- Rest of World 12%
Clinical Research brings in 92% of revenue.
Segments in detail